Major players in the cataract surgery devices and equipment market are Alcon Inc. , Abbott Laboratories, Carl Zeiss Meditech AG, Essilor International S. A. , Opcon Corporation, Allergan, Inc. , Bausch & Lomb, Inc.
New York, May 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cataract Surgery Devices And Equipment Global Market Report 2022" - https://www.reportlinker.com/p06277184/?utm_source=GNW , NIDEK Co. Ltd., STAAR Surgical Company, and Johnson & Johnson. The global cataract surgery devices and equipment market is expected to grow from $5.95 billion in 2021 to $6.58 billion in 2022 at a compound annual growth rate (CAGR) of 10.6%. The market is expected to grow to $9.13 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The cataract surgery devices and equipment market consist of sales of cataract surgery devices and equipment and related services. Cataract surgery devices and equipment include instruments used for performing cataract surgeries such as small incision cataract surgery and extracapsular surgery in the treatment of cataracts, a condition in which the lens of the eye becomes progressively opaque, resulting in blurred vision. The main types of cataract surgery devices and equipment are intraocular lens (IOL), ophthalmic viscoelastic device (OVD), phacoemulsification equipment, and femtosecond laser equipment.An ophthalmic viscoelastic device (OVD) is used for performing cataract surgeries. The cataract surgery devices and equipment are used for various surgery types such as extracapsular cataract extraction, phacoemulsification, femtosecond laser, and others. These are used by end-users such as ophthalmology centers, hospitals, and clinics. North America was the largest region in the cataract surgery devices and equipment market in 2021.Asia Pacific was the second-largest region in cataract surgery devices and equipment market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The major growth driver for this industry has been the global aging population.In 2019, there were 703 million persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. The cases of cataracts in the geriatric population are also expected to increase in the same proportion. According to World Health Organization, the number of cataract cases is expected to increase by 78% by 2050 in the U.S. alone. This presents a huge market for cataract surgery equipment manufacturers shortly by expanding the customer base due to the fast-growing geriatric population. For instance, the population of China is getting older faster than anywhere else in the world, this presents a huge market for the cataract surgery device manufacturers in China. The major challenge that is faced by this industry is the low level of awareness about eye disorders, especially cataracts.Many people do not have proper knowledge about the symptoms of cataracts and do not get the treatment done. This leads to potential revenue loss for the cataract surgery device manufacturers because of the low number of end-users. For example, as per a study done by NCBI, out of 1552 respondents, 89.9% had heard of cataracts but only 42% were aware of any symptom of cataracts, low awareness of cataract symptoms acts as a major restraint for the cataract surgery equipment industry. The cataract surgery devices and equipment industry has witnessed many positive changes introduced by the market players, the most prominent one being the introduction of laser technology.Laser-assisted cataract surgery is used to gather information about the lens, to make the corneal incision, and for the opening in the lens capsule. The advent of laser technology has caused a significant impact on this industry by bringing in new levels of safety and accuracy and advancing cataract surgery.Femtosecond laser platforms have significantly contributed to the precision of cataract surgeries being performed and may soon surpass the traditional hand-held surgeries. For example, Abbott laboratories which lacked this technology, acquired Optimedica for $250 million to enter the laser cataract surgery devices market after witnessing the huge demand and benefits of laser technology. The ophthalmology and medical equipment industry are subject to numerous stringent regulations and the cataract surgery device equipment manufacturers are no exception. These manufacturers need to comply with several regulations of which the European Medical Device Directives and the U.S. Health Care Compliance is the most prominent one. The European Medical Device Directive requires a manufacturer to meet the harmonized standards for placing their devices in the European market. Similarly the U.S. Health Care Compliance has laid down certain guidelines related to standards of business conduct to be followed by the Pharmaceutical manufacturers. The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates the safety of medical devices in the UK, has issued an urgent notice to Carl Zeiss Meditec, for voluntarily recalling a small batch of its intraocular lenses (IOL). The recall was initiated after the manufacturer detected mislabelling of its IOL, Aaren Scientific EC-3 hydrophobic lens with the wrong dioptric power. Therefore, the manufacturers need to comply strictly with the correct labeling of dioptric power on the IOLs. In March 2019, Alcon, a company manufacturing cataract surgery devices acquired PowerVision for a deal amount of $285 million.This acquisition, will implement the growth of the advanced technologies of intraocular lenses and also help the patients with their needs regarding cataract surgery. Power vision, a US-based company, is a medical device company operating in cataract surgical devices. The countries covered in the cataract surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. Read the full report: https://www.reportlinker.com/p06277184/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
(Bloomberg) -- Bill Gates has a short position against Tesla Inc. that would now need between $1.5 billion and $2 billion to close out, Elon Musk said Friday in a series of tweets.Most Read from BloombergElon Musk Says Bill Gates Has ‘Multi-Billion Dollar’ Tesla Short PositionRussian Wins in Eastern Ukraine Spark Debate Over Course of WarFord Beats Tesla to the Punch With First Electric F-150 DeliveryBitcoin Breaks From Stocks and Keeps On Falling as Crypto SlidesThe Richest Game in World Footba
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Many Americans are surprised to see they have not prepared as well as they had hoped for retirement when they finally get ready to call it quits. The bad news is, you’ll probably have to make some realistic assumptions of what your retirement will look like. If you’ve lived primarily paycheck to paycheck in your working years, that may continue to feel the case in your retirement.
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge, such as Google, Microsoft and Nvidia.
Here's what a fundamental and technical analysis says about Google stock. GOOGL stock buybacks remain high as web search and YouTube advertising rebound. But cloud computing growth is key.
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
(Bloomberg) -- Fertilizer prices that had hit records are now plunging as buyers reel from sticker shock, but that doesn’t mean the market squeeze is over. Most Read from BloombergElon Musk Says Bill Gates Has ‘Multi-Billion Dollar’ Tesla Short PositionRussian Wins in Eastern Ukraine Spark Debate Over Course of WarFord Beats Tesla to the Punch With First Electric F-150 DeliveryBitcoin Breaks From Stocks and Keeps On Falling as Crypto SlidesThe Richest Game in World Football Isn’t the One You Thi
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
Billions of dollars have been poured into companies seeking early detection of cancer through common blood draws.
The highest paid CEOs in America in 2021, according to Fortune's new analysis of executive pay.
To the public, the monkeypox outbreak has echoes of the early days of the COVID-19 pandemic. But scientists say it's not the same at all.
When Warren Buffett, the CEO of conglomerate Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), buys or sells a stock, Wall Street and investors tend to pay close attention. Since taking the reins, Buffett has created close to $670 billion in value for his shareholders (which includes himself), and he's led his company's Class A shares (BRK.A) to an almost unfathomable 20.1% average annual return. To put this performance in another context, the benchmark S&P 500 has "only" gained 30,209%, including dividends paid, since Buffett took over Berkshire Hathaway.
Women CEOs were paid a median $15.8 million in 2021, according to a new report.
This is also a good time to examine your investment portfolio. Procter & Gamble (NYSE: PG) sells basic items that people use regularly, no matter what's happening in the economy. For the fiscal third quarter (ended March 31), Procter & Gamble's sales, excluding foreign currency translations, rose by 10%, with price increases accounting for 5% and increased volume responsible for 3% (a change in mix represented the balance).
An Israeli private investigator currently in U.S. custody used Indian hackers to conduct surveillance operations for ultra-wealthy Russians, a reporter said in a court filing late Wednesday. Independent journalist Scott Stedman told a court in New York that jailed private detective Aviram Azari worked "on surveillance and cyber-intelligence operations at the behest of Russian oligarchs," citing a mix of public reporting and confidential sources. Stedman said in a declaration that one of the Russian oligarchs concerned was aluminum tycoon Oleg Deripaska, whom he said indirectly employed Azari in connection with a business dispute in Austria.
Kwasi Kwarteng has asked National Grid to bolster electricity supplies using coal this winter amid concerns Russia’s supply of gas to Europe will be cut off.
Stock splits have been all the rage in recent years, fueled by surging stock prices of some of the world's most recognizable companies. Worse still, the tech-heavy Nasdaq has tumbled into bear market territory, down roughly 27% from its high reached late last year. Read on to find out why they picked Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), and Shopify (NYSE: SHOP) from among the recent stock-split candidates.
The bank launched a digital challenger bank in the U.K. eight months ago and is seeing solid results already.